BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies (P9-2.010)
To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational TYK2/JAK1 inhibitor in healthy adults.
Authors
- Bruce D. Car
- Irfan Qureshi (ORCID: https://orcid.org/0000-0002-0572-0993)
- Jo Ann Malatesta
- Richard Bertz (ORCID: https://orcid.org/0009-0006-4593-1310)
- Randall Killingsworth
- Bavani Shankar
- Lindsey Lair (ORCID: https://orcid.org/0000-0002-5961-482X)
- Vlad Coric
- Janet Plummer
- Eric Ashbrenner
- Bharat Awsare
- Peter Ackerman
- Ratan D. Bhardwaj
Institutions
- Research and Studies Telecommunications Centre (TN)
- Biohaven Pharmaceuticals (United States) (US)
- Certara (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211559
- Primary Topic
- Cytokine Signaling Pathways and Interactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00